Contact Us
Drug Search Results
More Filters [+]

Zofin

Alternative Names: zofin, Organicell Flow, Organicell
Latest Update: 2024-10-01
Latest Update Note: News Article

Product Description

Organicell Regenerative Medicine is developing Zofin as a treatment for COVID-19, COPD, and Osteoarthritis. (Sourced from: https://organicell.com/zofin-2/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Nucleic Acid

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Pakistan

Approved Indications: None

Known Adverse Events: None

Company: Organicell Regenerative Medicine
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Zofin

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: Acute Lung Injury|Acute Respiratory Distress Syndrome|COVID-19|Respiratory Distress Syndrome, Newborn

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT05228899

P2

Completed

COVID-19

2023-10-01

25%
NCT04384445

P2

Completed

COVID-19|Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn

2023-07-01

35%

Recent News Events

Date

Type

Title

10/15/2024

News Article

 ZEO ScientifiX, a Leading South Florida Biotechnology Company, Launches Regenerative Medicine Educational Series for Physicians

10/01/2024

News Article

 ZEO ScientifiX Partners With National Provider of Healthcare Services

09/24/2024

News Article

 ZEO ScientifiX is Moving Toward Its Goal of Transforming Healthcare Through Leading-Edge Research

03/26/2024

News Article

 Global Exosome Market Size, Forecast, Trials and Trends Insights - Surging Number of Scientific Papers Investigating Exosomes and their Applications

03/19/2024

PubMed

 Hip Arthroscopy Simulator Training With Immersive Virtual Reality Has Similar Effectiveness to Nonimmersive Virtual Reality.

02/09/2024

PubMed

 Acellular Human Amniotic Fluid-Derived Extracellular Vesicles as Novel Anti-Inflammatory Therapeutics against SARS-CoV-2 Infection.

02/06/2024

PubMed

 A Descriptive, Retrospective Analysis of COVID-19 Passive Antibody Therapy and Its Effects on Morbidity and Mortality in Patients Receiving B-Cell-Depleting Therapies.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions